Rein Therapeutics, Inc. (RNTX): Cash & Equivalents
$3.21M
As of 2025-12-31
$8.54M
As of 2026-06-30
-14.8%
3-year compound annual growth
-14.5%
5-year compound annual growth
-1.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.21M | -75.0% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $12.87M | -25.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $17.31M | +233.3% | 2025-04-07, Balance as of period end |
| 2022-12-31 | $5.19M | +44.3% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $3.60M | -48.9% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $7.05M | +32.7% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $5.31M | -50.1% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $10.63M | -10.4% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $11.86M | -42.7% | 2019-03-29, Balance as of period end |
| 2016-12-31 | $20.71M | +449.8% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $3.77M | n/a | 2018-04-02, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $3.21M | -75.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare RNTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗